CO2020016718A2 - Terapia génica cardíaca con aav para cardiomiopatía - Google Patents

Terapia génica cardíaca con aav para cardiomiopatía

Info

Publication number
CO2020016718A2
CO2020016718A2 CONC2020/0016718A CO2020016718A CO2020016718A2 CO 2020016718 A2 CO2020016718 A2 CO 2020016718A2 CO 2020016718 A CO2020016718 A CO 2020016718A CO 2020016718 A2 CO2020016718 A2 CO 2020016718A2
Authority
CO
Colombia
Prior art keywords
aav
cardiomyopathy
gene therapy
cardiac gene
transgenes
Prior art date
Application number
CONC2020/0016718A
Other languages
English (en)
Inventor
Hugh Lee Sweeney
Margaret Mary Sleeper
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of CO2020016718A2 publication Critical patent/CO2020016718A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos útiles para tratar afecciones cardíacas. Las composiciones y métodos divulgados se basan en una terapia con AAV que comprende un vector de AAV recombinante para administrar dos o más transgenes al corazón de un sujeto, en donde los transgenes comprenden una proteína de la familia S100 y un inhibidor apoptótico. En algunos aspectos, el direccionamiento hacia múltiples fuentes de una o más afecciones cardíacas puede proporcionar beneficios sinérgicos durante el tratamiento.
CONC2020/0016718A 2018-06-08 2020-12-31 Terapia génica cardíaca con aav para cardiomiopatía CO2020016718A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682772P 2018-06-08 2018-06-08
US201962822015P 2019-03-21 2019-03-21
PCT/US2019/036157 WO2019237067A1 (en) 2018-06-08 2019-06-07 Aav cardiac gene therapy for cardiomyopathy

Publications (1)

Publication Number Publication Date
CO2020016718A2 true CO2020016718A2 (es) 2021-04-08

Family

ID=68770676

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0016718A CO2020016718A2 (es) 2018-06-08 2020-12-31 Terapia génica cardíaca con aav para cardiomiopatía

Country Status (14)

Country Link
US (1) US20210260215A1 (es)
EP (1) EP3814512A4 (es)
JP (1) JP2021526818A (es)
KR (1) KR20210018902A (es)
CN (1) CN112272705A (es)
AU (1) AU2019282822A1 (es)
BR (1) BR112020024935A2 (es)
CA (1) CA3100280A1 (es)
CL (1) CL2020003190A1 (es)
CO (1) CO2020016718A2 (es)
IL (1) IL279225A (es)
MX (1) MX2020013313A (es)
SG (1) SG11202011061SA (es)
WO (1) WO2019237067A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016126A1 (en) * 2019-07-19 2021-01-28 University Of Florida Researchfoundation, Incorporated Aav cardiac gene therapy for cardiomyopathy in humans
MX2023000994A (es) * 2020-08-05 2023-03-01 Spacecraft Seven Llc Genoterapia con csrp3 (proteina 3 rica en cisteina y glicina).
MX2023007602A (es) 2020-12-23 2023-09-21 Univ Florida Mayor eficiencia del empaquetamiento de vectores para terapia genica cardiaca.
WO2023166026A1 (en) * 2022-03-02 2023-09-07 Cevec Pharmaceuticals Gmbh Improved cell lines and methods for the production of adeno-associated vectors
EP4239063A1 (en) * 2022-03-02 2023-09-06 CEVEC Pharmaceuticals GmbH Improved cell lines and methods for the production of adeno-associated vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914029A1 (en) * 2013-06-07 2014-12-11 The Regents Of The University Of California Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
CN116440292A (zh) * 2016-01-19 2023-07-18 加利福尼亚大学董事会 Danon病和其它自噬障碍的治疗方法

Also Published As

Publication number Publication date
JP2021526818A (ja) 2021-10-11
CL2020003190A1 (es) 2021-04-30
MX2020013313A (es) 2021-02-22
IL279225A (en) 2021-01-31
SG11202011061SA (en) 2020-12-30
EP3814512A4 (en) 2022-03-09
CN112272705A (zh) 2021-01-26
AU2019282822A1 (en) 2020-11-26
CA3100280A1 (en) 2019-12-12
BR112020024935A2 (pt) 2021-03-09
EP3814512A1 (en) 2021-05-05
KR20210018902A (ko) 2021-02-18
WO2019237067A1 (en) 2019-12-12
US20210260215A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CO2020016718A2 (es) Terapia génica cardíaca con aav para cardiomiopatía
CL2022000115A1 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos.
PE20211419A1 (es) Vectores virales recombinantes y acidos nucleicos para producirlos
BR112022002905A2 (pt) Composições e métodos para modular splicing e expressão de proteína
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
BR112022009279A2 (pt) Tratamento de angioedema hereditário com vetores de terapia gênica específicos do fígado
BR112022002794A2 (pt) Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1
EA202092654A1 (ru) Генная терапия сердца с помощью aav при кардиомиопатии
CL2023001731A1 (es) Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca.
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir
DOP2023000132A (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
MX2022007453A (es) Potenciacion de tratamiento contra helmintos.
ZA202102023B (en) Potentiation of helminth treatment
EA202090506A1 (ru) Композиции и способы лечения заболеваний и расстройств печени, ассоциированных с одним или обоими состояниями из числа гипераммонемии или атрофии мышц
EA202090584A1 (ru) Антисмысловые олигомеры для лечения состояний и заболеваний
ECSP23093588A (es) Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva
AR116493A1 (es) Composiciones y métodos para tratar la retinosis pigmentaria
AR120249A1 (es) Vectores virales adeno-asociados para el tratamiento de la enfermedad de niemann-pick tipo c
AR120461A1 (es) Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado
EA202190513A1 (ru) Композиции и способы для лечения пигментного ретинита